MA29404B1 - Preparation pharmaceutique - Google Patents

Preparation pharmaceutique

Info

Publication number
MA29404B1
MA29404B1 MA30318A MA30318A MA29404B1 MA 29404 B1 MA29404 B1 MA 29404B1 MA 30318 A MA30318 A MA 30318A MA 30318 A MA30318 A MA 30318A MA 29404 B1 MA29404 B1 MA 29404B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical preparation
aberrational
pkt
activity
treatment
Prior art date
Application number
MA30318A
Other languages
English (en)
French (fr)
Inventor
Barry Howard Carter
Dwayne A Campbell
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29404(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MA29404B1 publication Critical patent/MA29404B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA30318A 2005-04-19 2007-10-25 Preparation pharmaceutique MA29404B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
MA29404B1 true MA29404B1 (fr) 2008-04-01

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30318A MA29404B1 (fr) 2005-04-19 2007-10-25 Preparation pharmaceutique

Country Status (28)

Country Link
US (3) US8821927B2 (enExample)
EP (1) EP1871347B1 (enExample)
JP (1) JP5202302B2 (enExample)
KR (1) KR101356748B1 (enExample)
CN (1) CN101203211B (enExample)
AR (1) AR054252A1 (enExample)
AU (1) AU2006236423B2 (enExample)
BR (1) BRPI0609962B1 (enExample)
CA (1) CA2606207C (enExample)
CY (1) CY1118179T1 (enExample)
DK (1) DK1871347T3 (enExample)
EA (1) EA200702253A1 (enExample)
ES (1) ES2601503T3 (enExample)
HR (1) HRP20161429T1 (enExample)
HU (1) HUE030982T2 (enExample)
IL (1) IL186336A0 (enExample)
LT (1) LT1871347T (enExample)
MA (1) MA29404B1 (enExample)
MX (1) MX2007013089A (enExample)
NO (1) NO20075111L (enExample)
NZ (1) NZ562223A (enExample)
PE (1) PE20061430A1 (enExample)
PL (1) PL1871347T3 (enExample)
PT (1) PT1871347T (enExample)
SI (1) SI1871347T1 (enExample)
TW (1) TW200716204A (enExample)
WO (1) WO2006113649A1 (enExample)
ZA (1) ZA200708705B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101356748B1 (ko) * 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
JP5858989B2 (ja) 2010-05-21 2016-02-10 ノバルティス アーゲー 組合せ
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP2958552B1 (en) * 2013-02-19 2017-06-21 Hexal AG Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SK146199A3 (en) 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
US7141576B2 (en) 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
KR101356748B1 (ko) * 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물

Also Published As

Publication number Publication date
BRPI0609962A2 (pt) 2011-10-11
EP1871347A1 (en) 2008-01-02
JP5202302B2 (ja) 2013-06-05
CN101203211A (zh) 2008-06-18
AR054252A1 (es) 2007-06-13
KR101356748B1 (ko) 2014-02-06
MX2007013089A (es) 2008-01-14
ES2601503T3 (es) 2017-02-15
HUE030982T2 (en) 2017-06-28
NO20075111L (no) 2007-11-16
PT1871347T (pt) 2016-11-10
PL1871347T3 (pl) 2017-04-28
AU2006236423B2 (en) 2009-12-10
US20080206330A1 (en) 2008-08-28
US20160143909A1 (en) 2016-05-26
CA2606207A1 (en) 2006-10-26
WO2006113649A1 (en) 2006-10-26
HRP20161429T1 (hr) 2016-12-16
US20140335177A1 (en) 2014-11-13
IL186336A0 (en) 2008-01-20
DK1871347T3 (en) 2016-11-28
US8821927B2 (en) 2014-09-02
AU2006236423A1 (en) 2006-10-26
EP1871347A4 (en) 2012-10-31
SI1871347T1 (sl) 2016-11-30
ZA200708705B (en) 2009-12-30
BRPI0609962B1 (pt) 2022-01-18
LT1871347T (lt) 2016-11-10
JP2008536931A (ja) 2008-09-11
CA2606207C (en) 2014-11-18
EP1871347B1 (en) 2016-08-03
NZ562223A (en) 2010-01-29
CY1118179T1 (el) 2017-06-28
PE20061430A1 (es) 2007-01-25
CN101203211B (zh) 2012-08-08
TW200716204A (en) 2007-05-01
KR20080005557A (ko) 2008-01-14
EA200702253A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l'activité de gpr119
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
EP1848270A4 (en) TRANSMUCOSAL ADMINISTRATION OF MEDICINAL PREPARATIONS FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MA31373B1 (fr) Composes amino-heterocycliques
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
TNSN03130A1 (en) HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THEM, PHARMACEUTICAL USES THEREOF AND MATERIALS FOR THEIR SYNTHESIS
MA34474B1 (fr) Agonistes de gpr40
EP2007435A4 (en) TARGETED TREATMENT SYSTEM
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
ATE312815T1 (de) Neue verbindungen
EA200702253A1 (ru) Фармацевтическая композиция